JP2003516325A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516325A5
JP2003516325A5 JP2001541001A JP2001541001A JP2003516325A5 JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5 JP 2001541001 A JP2001541001 A JP 2001541001A JP 2001541001 A JP2001541001 A JP 2001541001A JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5
Authority
JP
Japan
Prior art keywords
epilepsy
stroke
group
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001541001A
Other languages
English (en)
Other versions
JP2003516325A (ja
JP4021195B2 (ja
Filing date
Publication date
Priority claimed from US09/454,136 external-priority patent/US6605597B1/en
Application filed filed Critical
Publication of JP2003516325A publication Critical patent/JP2003516325A/ja
Publication of JP2003516325A5 publication Critical patent/JP2003516325A5/ja
Application granted granted Critical
Publication of JP4021195B2 publication Critical patent/JP4021195B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【請求項２６】 該組成物が、癲癇および脳卒中よりなる群から選択される中枢神経系障害を受けた哺乳動物に投与される、請求項２１に記載の医薬組成物。
【請求項３９】 該薬剤が、癲癇および脳卒中よりなる群から選択される中枢神経系障害を受けた哺乳動物への投与に適する、請求項３５に記載の使用。
JP2001541001A 1999-12-03 2000-12-01 部分もしくは完全ａ１アゴニスト：ｎ６複素環式５′−チオ置換アデノシン誘導体 Expired - Fee Related JP4021195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US09/454,136 1999-12-03
PCT/US2000/032721 WO2001040246A1 (en) 1999-12-03 2000-12-01 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives

Publications (3)

Publication Number Publication Date
JP2003516325A JP2003516325A (ja) 2003-05-13
JP2003516325A5 true JP2003516325A5 (ja) 2007-10-11
JP4021195B2 JP4021195B2 (ja) 2007-12-12

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001541001A Expired - Fee Related JP4021195B2 (ja) 1999-12-03 2000-12-01 部分もしくは完全ａ１アゴニスト：ｎ６複素環式５′−チオ置換アデノシン誘導体

Country Status (25)

Country Link
US (2) US6605597B1 (ja)
EP (1) EP1233973B1 (ja)
JP (1) JP4021195B2 (ja)
KR (1) KR100484988B1 (ja)
CN (1) CN1152042C (ja)
AR (1) AR029199A1 (ja)
AT (1) ATE254133T1 (ja)
AU (3) AU4138701A (ja)
BR (1) BR0016126A (ja)
CA (1) CA2389264C (ja)
CZ (1) CZ20013705A3 (ja)
DE (1) DE60006576T2 (ja)
DK (1) DK1233973T3 (ja)
ES (1) ES2208437T3 (ja)
HK (1) HK1047941A1 (ja)
HU (1) HUP0500455A2 (ja)
IL (1) IL145903A (ja)
MX (1) MXPA01011113A (ja)
NO (1) NO20015373L (ja)
NZ (1) NZ514777A (ja)
PT (1) PT1233973E (ja)
TR (2) TR200103129T2 (ja)
TW (1) TWI249536B (ja)
WO (2) WO2001040243A2 (ja)
ZA (1) ZA200204380B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
MXPA04008008A (es) * 2002-02-19 2005-03-23 Cv Therapeutics Inc Agonistas parciales y completos de receptores de adenosina a1.
EP1494685B1 (en) * 2002-04-18 2008-12-31 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
WO2005040174A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
KR101494125B1 (ko) 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP2066232A1 (en) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
WO2008086096A2 (en) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Myocardial perfusion imaging
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009114533A2 (en) 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM
WO2009128933A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
EP0764639A4 (en) * 1994-06-09 1997-10-01 Ss Pharmaceutical Co 4-CHINOLINONE DERIVATIVE OR ITS SALT
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives

Similar Documents

Publication Publication Date Title
JP2003516325A5 (ja)
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
JP2003503454A5 (ja)
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
JP2002502871A5 (ja)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2005532372A5 (ja)
JP2002511411A5 (ja)
JP2002532392A5 (ja)
JP2004525194A5 (ja)
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
BG108131A (en) Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
JP2004527551A5 (ja)
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
JP2022153638A5 (ja)
TW197423B (ja)
Bacsik et al. Toxic systemic reactions of bupivacaine and etidocaine
EP1440689A3 (en) Treatment of neurotic disorders
JP2001513504A5 (ja)
EE200300139A (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
HUP0301578A3 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
JP2003522147A5 (ja)